Overall, the pharmacological and safety properties of the RAC1 inhibitor A41 open up prospects for clinical trials aimed at assessing the risks and benefits of targeting RAC1 in human cancer, particularly in breast cancer. This evidence concerns the gene RAC1 and breast cancer.